Emiltatug ledadotin — Investigational Agent
Antibody-Drug Conjugate · Phase 1 · Mersana Therapeutics
Mechanism of Action
Emiltatug ledadotin is a B7-H4-directed antibody-drug conjugate built on Mersana's Dolasynthen platform, carrying an auristatin-based (DolaLock) payload with controlled bystander effect at a defined drug-to-antibody ratio. B7-H4 is an immune-checkpoint ligand overexpressed in breast (including TNBC and HR+), ovarian, and endometrial cancers with limited normal-tissue expression. After binding B7-H4, the ADC is internalized and releases its microtubule-inhibitor payload to drive mitotic arrest and apoptosis. The controlled bystander mechanism enables activity in tumors with heterogeneous…
Investigational Indications
- Triple-negative breast cancer
- HR+/HER2- breast cancer
- B7-H4-expressing ovarian cancer
- Endometrial cancer
- Adenoid cystic carcinoma